Medtronic just announced European approval of its Evera implantable cardioverter-defibrillators (ICD). The product line features a long battery life that can stretch to up to 11 years, a new slick shape that reduces skin pressure, and Sprint Quattro Secure leads that have been shown to last 10 years with active monitoring.
The implants also sport the new SmartShock 2.0 technology that improves on its predecessor in preventing unnecessary shocks and makes the device easier to program.
Advancing Medtronic’s exclusive SmartShock Technology™ – an improved shock reduction algorithm that enables the device to better differentiate between dangerous and harmless heart rhythms, and delivers a 98-percent inappropriate shock free rate at one year – the Evera system includes SmartShock™ 2.0, the next-generation version of the technology.11 SmartShock 2.0 enhances shock reduction with added performance and simplified programming. Also included in the new ICD portfolio is OptiVol® 2.0 Fluid Status Monitoring and complete diagnostics, which helps to identify patients at risk of worsening heart failure and atrial fibrillation.